Home » Schering-Plough's Pegintron and Rebetol Combination Therapy Approved in EU
Schering-Plough's Pegintron and Rebetol Combination Therapy Approved in EU
Schering-Plough Corp. said the European Commission last month approved its 48-week standard-dose Pegintron and Rebetol combination therapy for chronic hepatitis C in adult patients whose prior treatment with interferon alpha and ribavirin combination therapy or interferon alpha monotherapy did not result in a sustained response.
Sharewatch
Sharewatch
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May